BNP Paribas Asset Management Holding SA saw its position in BioNTech SE (NASDAQ:BNTX – Get Rating) decline by 31.6% in the fourth quarter, according to the company’s latest filings with the SEC. The institutional investor held 8,238 shares in the company after selling 3,804 shares during the quarter. His BioNTech holding in BNP Paribas Asset Management Holding SA was valued at $1,238,000 as of the latest filing with the SEC.
Several other hedge funds and institutional investors have also changed their stakes in the company. Captrust Financial Advisors raised his BioNTech stock holding by 6.9% in the second quarter. Captrust Financial Advisors purchased an additional 69 shares during the period and now owns 1,068 shares of the company, valued at $159,000. Centaurus Financial Inc. boosted his BioNTech stock position by 5.2% in the first quarter. Centaurus Financial Inc. purchased an additional 71 shares during the period and now owns 1,448 shares of the company, valued at $247,000. Green Alpha Advisors LLC increased his BioNTech holding by 2.9% in the fourth quarter. Green Alpha Advisors LLC purchased an additional 97 shares during the period and now owns 3,406 shares of the company stock valued at $512,000. Midwest Professional Planners Inc. BioNTech’s stock position increased 6.0% during the third quarter. Midwest Professional Planners, Inc. purchased an additional 106 shares last quarter and now owns 1,885 shares of the company, valued at $254,000. Finally, the National Bank of Canada FI increased his BioNTech stake holding by 21.3% in the fourth quarter. The National Bank of Canada FI acquired an additional 115 shares during the last quarter and now owns 655 shares, valued at $98,000. Currently 15.29% of the shares are owned by hedge funds and other institutional investors.
Wall Street analysts forecast growth
BNTX has been the subject of many recent research reports. Wainwright HC reiterated his Buy rating in a research note on Thursday, March 30, setting a $210.00 price target on BioNTech stock. Bank of America cut its price target on BioNTech stock from $239.00 to $194.00 in its Monday, March 27 report, setting the company’s valuation at Buy. Berenberg Bank set a target price for BioNTech at $260.00 in a report on Tuesday, March 28. Goldman Sachs Group set a price target on BioNTech at $140.00 in a research note on Tuesday, March 28, giving the stock a “neutral” rating. Finally, in a report Wednesday, Redburn Partners upgraded BioNTech’s stock from a Neutral rating to a Buy rating and raised its price target from $165.00 to $170.00. Seven research analysts rate the stock as a “hold” and six rate it as a “buy.” Based on MarketBeat.com data, the company has a consensus rating of Hold and an average target price of $173.00.
BioNTech deals up 1.5%
BNTX shares rose $1.54 on Friday to $106.49. The trading volume for this stock was 110,917 shares for him, with an average volume of 680,663 shares. The company has a current ratio of 12.95, a quick ratio of 12.68 and a debt to equity ratio of 0.01. The company has a 50-day moving average price of $120.06 and a 200-day moving average price of $140.54. BioNTech SE hit a 12-month low of $100.08 and a 12-month high of $188.99. The company has a market capitalization of $25.9 billion, a P/E of 4.03 times, and a beta of 0.21 times.
BioNTech (NASDAQ:BNTX – Get Rating) last reported quarterly results on Monday, May 8th. The company reported earnings of $2.05 a share for the quarter, beating analyst consensus expectations of $0.18 by $1.87. The business had sales of $1.28 billion in the quarter, up from $1.09 billion expected by analysts. BioNTech’s return on equity was 32.52% and net profit margin was 51.03%. The company’s revenue for the quarter fell 80.0% year-on-year. His EPS for the same business in the same period last year was $15.98. Analysts expect the group as a whole to see BioNTech SE’s earnings per share of 5.32 for the current financial year.
BioNTech Company Profile
BioNTech SE is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing his FixVac product candidates, including his BNT111, which is in Phase II clinical trials for advanced melanoma. BNT112 is in Phase I/IIa clinical trials for prostate cancer. BNT113 is in Phase II clinical trials to treat HPV+ head and neck cancer. BNT114 is in Phase I clinical trials for triple-negative breast cancer. BNT115 is in Phase I clinical trials for ovarian cancer. BNT116 is a preclinical product for non-small cell lung cancer.
Want to know if other hedge funds are holding BNTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for BioNTech SE (NASDAQ:BNTX – Get Rating).
This instant news alert was generated by MarketBeat’s narrative science technology and financial data to provide our readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments regarding this story to firstname.lastname@example.org.
Listen to this before you consider BioNTech.
MarketBeat tracks Wall Street’s highest-rated, highest-performing research analysts and the stocks they recommend to clients every day. MarketBeat has identified five stocks top analysts are secretly whispering to customers to buy now before the whole market goes viral…and BioNTech isn’t on that list.
BioNTech currently has a ‘Hold’ rating among analysts, but highly rated analysts think these five stocks are better buys.
Click here for 5 brands